Daniel Ahn

[Daniel Ahn @the_danielahn]

@manjuggm @pashtoonkasi @jonathanloree @IbrahimSahinMD1 Also with 5-FU. Confirmed on FDA/ASHP shortage websites…

[Daniel Ahn @the_danielahn]

@manjuggm @pashtoonkasi @jonathanloree @IbrahimSahinMD1 Not a rumor, there is a national shortage. We were informed several weeks ago, specifically in 500mg tabs.

[Daniel Ahn @the_danielahn]

@DucreuxMichel https://t.co/7TLiBUJbUp . @KoheiShitara REVERCE2 ongoing to confirm findings in US patients. 3. Similar studies have shown similar OS results . BACCI (https://t.co/5tzsKitLnn) @GIcancerDoc . 4. Why was SOLSTICE negative? TAS102/bev vs cape?

[Daniel Ahn @the_danielahn]

@DucreuxMichel After having time to think about the results, don’t believe the hype. The discussant failed to mention 3 key points. 1. Is this a bev naive effect (~30% had no prior bev exposure). 2 is this a sequencing effect? Rego has shown better OS when given in third line therapy (1/3)

[Daniel Ahn @the_danielahn]

NAPOLI-3 positive. Historical retrospective data suggests no difference in survival between FOLFIRINOX and gem abraxane. Maybe naliri isn’t the same as iri? Looking forward to see data. ⁦@GIcancerDoc⁩ https://t.co/0gRBzXpCOI

[Daniel Ahn @the_danielahn]

@GIcancerDoc @KReissMD @EileenMOReilly @ALLIANCE_org 😂

[Daniel Ahn @the_danielahn]

@AdamSchefter @SameerKeoleMD

[Daniel Ahn @the_danielahn]

@R_Brauninger That’s the take home? Should be: 1. O line is terrible, Aki needs to take a seat permanently on the bench. 2. Jimbo needs an OC and 3. Jimbo needs an OC. Play call, time management (wasted two timeouts in the second half).

[Daniel Ahn @the_danielahn]

@fireflyann @Jcj84Jeremy Open in Mayo AZ as well

[Daniel Ahn @the_danielahn]

Thank you for the opportunity to speak at this event for this great endeavor! @GIcancerDoc @MayoCancerCare

[A.n.n. @fireflyann]

Next up at @KRASKickers Connect Patient conference today.

Targeting KRAS: From the
“Undruggable” to Druggable in Colorectal Cancer
Daniel Ahn, D.O. , M.S. , Mayo Clinic

@the_danielahn @MayoClinic

[Daniel Ahn @the_danielahn]

@OncoJurdi Congrats Adham!

[Daniel Ahn @the_danielahn]

@MarkYarchoan @graokane Sounds like from the press release, PFS was also missed which cannot be attributed to second line ICIs. It will be interesting to see the data.

[Daniel Ahn @the_danielahn]

@GABOUALFA Thanks Ghassan. Disappointing but not shocking. Landscape is becoming clearer for first line. “Line minus one is now line none.”

[Daniel Ahn @the_danielahn]

@Amitmahipal79 @MayoCancerCare @UHhospitals @jorgegarcia @TedTeknosMD @doctorC369 Congrats Amit and Sakti!

[Daniel Ahn @the_danielahn]

@drjasonstarr @RManochakian Loving that linen suit Jason!

[Tanios Bekaii-Saab, MD @GIcancerDoc]

@the_danielahn @DrChowdharyMD @SprakerMDPhD @freddyeescorcia @chadinabhan @MayoCancerCare @rweichselbaum @jmmrad @subatomicdoc @MikeChuongMD @JoeHermanMD @olusolaodavies @KrishanJethwa @RadDocMReyngold “Given that olaparib is expensive and relatively toxic, and in the absence of a clear survival benefit, it may be difficult to justify its use”

[Daniel Ahn @the_danielahn]

@DrChowdharyMD @SprakerMDPhD @freddyeescorcia @chadinabhan @GIcancerDoc @MayoCancerCare @rweichselbaum @jmmrad @subatomicdoc @MikeChuongMD @JoeHermanMD @olusolaodavies @KrishanJethwa @RadDocMReyngold I agree with you 💯 on olaparib @GIcancerDoc https://t.co/IO6tYPFERb

[Dr. jordan berlin @jordanberlin5]

It is time we started treating radiation as experimental therapy in pancreatic cancer and found a way to prove its utility. I still use it where I believe it helps--such things as clearing margins and getting people time off systemic therapy, but would be nice to prove benefit

[Daniel Ahn @the_danielahn]

@NiuSanford @GIcancerDoc He’s the best

[Daniel Ahn @the_danielahn]

@NiuSanford @GIcancerDoc Weird, no. Must be Elon Musk 🤷🏻‍♂️